Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture
Independent valuation reflects major advancement of OT-101 and Deciparticle™ nanomedicine platform SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) — via IBN — Oncotelic Therapeutics, Inc. (OTLC) today announces that its joint venture partner, GMP Bio, has completed
(Financial Post, 2025-11-20T12:58:37Z)